drugset / Trial / NCT00927732

Hydroquinidine Versus Placebo in Patients With Brugada Syndrome

NCT00927732 ↗

Phase 3 Terminated 64 enrolled Nantes University Hospital Sanofi · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The specific aim of this study is to determine whether hydroquinidine administration can prevent heart from appearance of ventricular arrhythmia detected by the automatic implantable defibrillator (ICD).

Timeline

Start
2009-02
Primary completion
2014-10
Completion
2014-10

Outcome

Outcome not reported

Stopped (Enrollment): “insufficient recruitment, a lot of premature study discontinuations”

Drugs

EvaluationDrugModalityDoseRoute
Subject hydroquinidine Small molecule 300 mg —

Indications